Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review

@article{Lukka2006MaximalAB,
  title={Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review},
  author={Himu R Lukka and Tricia S Waldron and Laurence H. Klotz and Eric William Winquist and John Trachtenberg},
  journal={Current Oncology},
  year={2006},
  volume={13},
  pages={81 - 93}
}
INTRODUCTION Maximal androgen blockade (MAB) versus castration alone in patients with metastatic prostate cancer has been extensively evaluated in randomized trials. The inconsistent results have led to the publication of multiple meta-analyses. The present review examines the evidence from meta-analytic reports to determine whether MAB using agents such as flutamide, nilutamide, and cyproterone acetate (CPA) is associated with a survival advantage. METHODS We conducted a systematic review of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

AR function in promoting metastatic prostate cancer

Cancer and Metastasis Reviews • 2013
View 4 Excerpts
Highly Influenced

Roles of Prohibitin in Growth Control and Tumor Suppression in Human Cancers

Translational oncogenomics • 2008
View 4 Excerpts
Highly Influenced

Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 65 references

Change of endocrine therapy for advanced prostate cancer: results of meta-analysis [Japanese

H Shiina, M. Igawa
Ni hinihon J Urol 1999;61:389–94 • 1999

Similar Papers

Loading similar papers…